Home > News > Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
January 20th, 2003
Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
Targesome Inc., co-founded by Drs. King Li and Mark Bednarski in late 1999, is developing nanoparticles that can be used for drug delivery. Any drug can be attached to the surface of the nanoparticle, resulting in improved therapeutic properties such as efficacy, safety, and increased half-life in the blood for small molecule drugs (thereby allowing less frequent intravenous dosing).
Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014
Tokyo Institute of Technology research: Protein-engineered cages aid studies of cell functions November 19th, 2014
A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014
Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT November 18th, 2014